Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 13;11:16867. doi: 10.1038/s41598-021-95732-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Probability of achieving therapy free responses (TFR). Proportion of patients achieving TFR within the whole cohort (n = 121) included in the study (panel a), and in those with chronic ITP (panel b). TFR was defined as the ability of a patient to discontinue TPO-RA as platelet counts > 50 × 10⁹/l for at least 6 months in the absence of any therapies meant to increase platelet counts. Patients who died while on TPO-RA therapy were not included in the study. Solid black line represents patients that received only romiplostim (Panel a, n = 41; Panel b, n = 29). Solid grey line represents patients that received only eltrombopag (Panel a, n = 41; Panel b, n = 24). Dashed black line represents patients that initiated romiplostim and switched to eltrombopag (Panel a, n = 13; Panel b, n = 8). Dashed grey line represents patients that initiated eltrombopag and switched to romiplostim (Panel a, n = 26; Panel b, n = 21). The number of patients under TPO therapy (“at risk”) and the cumulative TFR at time points are presented for each group below each figure.